Related Experiment Video
Updated: May 1, 2026
13:27
A Novel Surgical Technique As a Foundation for In Vivo Partial Liver Engineering in Rat
Published on: October 6, 2018
7.8K
Buprenorphine implant for opioid addiction
1Department of Psychiatry & Biobehavioral Sciences, David Geffen School of Medicine at UCLA, 1640 S. Sepulveda Blvd, Suite 120, Los Angeles, CA 90025-7535, USA. lwalter@ix.netcom.com.
Pain Management
|March 25, 2014
Summary
The buprenorphine implant offers a novel delivery system for opioid addiction treatment, enhancing medication compliance and reducing misuse potential. This long-acting formulation aims to improve therapeutic benefits for patients with opioid dependence.
Area of Science:
- Pharmacology
- Addiction Medicine
- Drug Delivery Systems
Background:
- Buprenorphine, a partial opioid agonist, is a standard treatment for opioid addiction when administered daily via sublingual tablets.
- Current sublingual formulations face challenges with medication compliance, potential for misuse, and diversion.
- A long-acting formulation aims to overcome these limitations and improve patient outcomes.
Purpose of the Study:
- To review the development and potential benefits of the buprenorphine implant (Probuphine™) as a novel long-acting formulation for opioid addiction management.
- To discuss the innovative delivery system and its advantages over traditional sublingual buprenorphine.
- To highlight the potential for improved medication compliance and reduced misuse.
Main Methods:
- Review of existing research reports and scientific literature on buprenorphine implants.
- Analysis of clinical research data involving sublingual buprenorphine and the buprenorphine implant.
- Inclusion of author's clinical experience in treating opioid-dependent patients.
Main Results:
- The buprenorphine implant utilizes a subcutaneous delivery system with solid matrix 'rods' containing buprenorphine and ethylene vinyl acetate.
- This novel formulation is designed to ensure consistent medication delivery, thereby improving patient compliance.
- The implant aims to mitigate issues of misuse, abuse, and diversion associated with daily sublingual buprenorphine.
Conclusions:
- The buprenorphine implant represents an innovative advancement in delivering a proven medication for opioid addiction.
- This long-acting formulation has the potential to enhance therapeutic benefits by ensuring consistent buprenorphine levels and improving adherence.
- Further evaluation and regulatory approval (e.g., by the US FDA) are pending for this new treatment modality.
Related Concept Videos
01:15Opioid Analgesics: Synthetic and Semisynthetic Opioids
1.5K
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
1.5K
01:26Oral Drug Delivery Systems: Continuous-Release Systems
308
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
308
01:22Opioid Receptors: Overview
7.2K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
7.2K
01:21Intrauterine Drug Delivery Systems
168
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
168
01:20Opioid Analgesics: Morphine and Other Natural Cogeners
1.7K
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
1.7K
01:25Analgesia and Pain Management
3.3K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
3.3K